cholesteryl chloride | 96345-96-9

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: cholesteryl chloride
• 英文别名: 3-Chloro-5-cholestene；(8S,9S,10R,13R,14S,17R)-3-chloro-10,13-dimethyl-17-[(2R)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthrene
• CAS: 96345-96-9
• 化学式: C₂₇H₄₅Cl
• 分子量: 405.107
• InChiKey: OTVRYZXVVMZHHW-FNOPAARDSA-N

物化性质

• 沸点：
  478.6±14.0 °C(Predicted)
• 密度：
  0.99±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  9.8
• 重原子数：
  28
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.93
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  0

反应信息

• 作为反应物：
  描述：

  cholesteryl chloride 在 tBuOCrO3H 作用下， 生成 3β-chlorocholest-5-en-7-one
  参考文献：
  名称：

  Synthesis and in vitro antibacterial activity of new steroidal thiosemicarbazone derivatives

  摘要：

  We investigated the antibacterial activity of some new steroidal thiosemicarbazone derivatives, prepared from the reaction of cholest-5-en-7-one with thiosemicarbazides, in ethanol in the presence of a few drops of HCl at 80 degrees C in high yield. All the compounds have been characterized by means of elemental analyses, IR, H-1 NMR and mass spectroscopic data, to find an effective antibacterial agent. The antibacterial activity was first tested in vitro by the disk diffusion assay against two Gram-positive and two Gram-negative bacteria, and then the minimum inhibitory concentration (MIC) of compounds was determined. The results showed that the steroidal thiosemicarbazones derivatives inhibit growth of both types of the bacteria (Gram-positive and Gram-negative). The acetoxy and chloro derivatives of cyclopentyl and cyclohexyl amine thiosemicarbazones were found to have more antibacterial activity than the other derivatives. (C) 2008 Published by Elsevier Masson SAS.

  DOI：

  10.1016/j.ejmech.2007.12.004
• 作为产物：
  描述：

  胆固醇 在 氯化亚砜 作用下， 以 甲苯 为溶剂， 反应 72.0h， 以94%的产率得到cholesteryl chloride
  参考文献：
  名称：

  Fluorous Solvent as a New Phase-Screen Medium between Reagents and Reactants in the Bromination and Chlorination of Alcohols

  摘要：

  A perfluorohexane layer regulates the rate of reagent transport in the bromination and chlorination of alcohols. A fluorous triphasic U-tube method is effective for lighter reagents; the thionyl chloride layer (yellow) vanishes, and the chlorides are obtained from the right top organic layer in the chlorination of alcohols.

  DOI：

  10.1021/ol034060w
• 作为试剂：
  描述：

  (Z)-1-Phenyl-2-(2-benzophenanthrenyl)ethylene 、 (E)-1-Phenyl-2-(2-benzophenanthrenyl)ethylene 在 胆甾烯基豆蔻酸酯 、 碘 、 cholesteryl chloride 作用下， 以 neat (no solvent) 为溶剂， 反应 2.0h， 以85%的产率得到旋稠六苯
  参考文献：
  名称：

  Contribution of pitch and solute-solvent interactions to the photoasymmetric synthesis of hexahelicene in cholesteric liquid crystals

  摘要：

  DOI：

  10.1021/jo01314a044

文献信息

• Cationic amphiphiles containing steroid lipophilic groups for
  申请人：Genzyme Corporation

  公开号：US05747471A1

  公开（公告）日：1998-05-05

  Novel cationic amphiphiles are provided that facilitate transport of biologically active (therapeutic) molecules into cells. The amphiphiles contain lipophilic groups derived from steroids, from mono or dialkylamines, or from ether or ester-linked alkyl groups, and cationic groups, protonatable at physiological pH, derived from amines, alkylamines or polyalkylamines. There are provided also therapeutic compositions prepared typically by contacting a dispersion of one or more cationic amphiphiles with the therapeutic molecules. Therapeutic molecules that can be delivered into cells according to the practice of the invention include DNA, RNA, and polypeptides. Representative uses of the therapeutic compositions of the invention include providing gene therapy, and delivery of antisense polynucleotides or biologically active polypeptides to cells. With respect to therapeutic compositions for gene therapy, the DNA is provided typically in the form of a plasmid for complexing with the cationic amphiphile. Novel and highly effective plasmid constructs are also disclosed, including those that are particularly effective at providing gene therapy for clinical conditions complicated by inflammation.

  提供了一种新型的阳离子两性分子，可以促进生物活性（治疗性）分子进入细胞。这些两性分子包含从类固醇、单或双烷胺基、醚或酯键连接的烷基基团中衍生的亲脂基团，以及阳离子基团，可在生理pH下质子化，来自胺、烷胺或多烷基胺。还提供了通常通过将一个或多个阳离子两性分子的分散液与治疗分子接触而制备的治疗组合物。根据本发明的实践，可以将DNA、RNA和多肽等治疗分子输送到细胞中。本发明的治疗组合物的代表性用途包括提供基因治疗，以及将反义多核苷酸或生物活性多肽输送到细胞中。对于用于基因治疗的治疗组合物，DNA通常以质粒的形式提供，以与阳离子两性分子结合。还公开了新型且高效的质粒构建物，包括那些在为临床炎症并发症复杂的情况提供基因治疗方面特别有效的构建物。
• Cationic amphiphiles containing ester or ether-linked lipophilic groups
  申请人：Genzyme Corporation

  公开号：US05840710A1

  公开（公告）日：1998-11-24

  Novel cationic amphiphiles are provided that facilitate transport of biologically active (therapeutic) molecules into cells. The amphiphiles contain lipophilic groups derived from steroids, from mono or dialkylamines, or from alkyl or acyl groups; and cationic groups, protonatable at physiological pH, derived from amines, alkylamines or polyalkylamines. There are provided also therapeutic compositions prepared typically by contacting a dispersion of one or more cationic amphiphiles with the therapeutic molecules. Therapeutic molecules that can be delivered into cells according to the practice of the invention include DNA, RNA, and polypeptides. Representative uses of the therapeutic compositions of the invention include providing gene therapy, and delivery of antisense polynucleotides or biologically active polypeptides to cells. With respect to therapeutic compositions for gene therapy, the DNA is provided typically in the form of a plasmid for complexing with the cationic amphiphile. Novel and highly effective plasmid constructs are also disclosed, including those that are particularly effective at providing gene therapy for clinical conditions complicated by inflammation. Additionally, targeting of organs for gene therapy by intravenous administration of therapeutic compositions is described.

  提供了一种新型的阳离子两性分子，有助于将生物活性（治疗性）分子输送到细胞内。这些两性分子包含从类固醇、单或双烷胺基或烷基或酰基团衍生的亲脂基团；以及从胺、烷胺或多烷基胺衍生的在生理pH下可质子化的阳离子基团。还提供了通常通过将一个或多个阳离子两性分子的分散液与治疗分子接触而制备的治疗组合物。根据本发明的实践，可以将可输送到细胞内的治疗分子包括DNA、RNA和多肽。本发明的治疗组合物的代表性用途包括提供基因治疗，以及将反义多核苷酸或生物活性多肽输送到细胞中。关于用于基因治疗的治疗组合物，DNA通常以质粒的形式提供，以与阳离子两性分子结合。还公开了新型且高效的质粒构建物，包括那些在为临床炎症并发症复杂的情况下提供基因治疗方面特别有效的构建物。此外，描述了通过静脉给药治疗组合物来定位器官进行基因治疗的方法。
• POLYMER-CARBOHYDRATE CONJUGATES FOR DRUG DELIVERY TECHNOLOGY
  申请人：Wu Nian

  公开号：US20150157721A1

  公开（公告）日：2015-06-11

  The invention comprises compounds, methods of making, and methods of using. The compounds may have a linear or cylic backbone and three or four appended functional groups: one or two lipohilic compounds including sterols or “fat soluble” vitamins, one or two hydrophilic polymer, and one or two carbohydrate. A group of polymer-carbohydrate conjugates having a central backbone and three appended functional groups are disclosed wherein one lipophilic compound is void of both steroid acids. The conjugate may have fatty acids as the primary lipophilic carrier, one hydrophilic polymer, and one carbohydrate. Specific functional groups may be selected for specific applications in formulating pharmaceuticals, cosmetics, nutriceuticals, and the like. Typical coupling reaction of the conjugates may involve one or more or combinations or in series of alkylation including N-alkylation or O-alkylation, etherification, esterification and amidation chemical processes. A variety of linkers between the backbone and functional groups may also be selected to modify the carriers or center backbones for the coupling reactions and optimize performance of the conjugates.

  该发明包括化合物、制备方法和使用方法。这些化合物可能具有线性或环状的骨架，以及三个或四个附加的功能基团：一个或两个疏水化合物，包括固醇或“脂溶性”维生素，一个或两个亲水性聚合物，以及一个或两个碳水化合物。公开了一组具有中心骨架和三个附加功能基团的聚合物-碳水化合物共轭物，其中一个疏水性化合物不含类固醇酸。该共轭物可能以脂肪酸作为主要疏水载体，一个亲水性聚合物和一个碳水化合物。特定的功能基团可以根据在制备药物、化妆品、营养保健品等方面的具体应用而选择。共轭物的典型偶联反应可能涉及一种或多种或组合或串联的烷基化，包括N-烷基化或O-烷基化，醚化，酯化和酰胺化化学过程。还可以选择各种连接剂连接骨架和功能基团之间，以修改载体或中心骨架以进行偶联反应并优化共轭物的性能。
• [EN] METHOD OF CONVERTING ALCOHOL TO HALIDE<br/>[FR] PROCÉDÉ DE CONVERSION D'UN ALCOOL EN HALOGÉNURE
  申请人：UNIV SAARLAND

  公开号：WO2016202894A1

  公开（公告）日：2016-12-22

  The present invention relates to a method of converting an alcohol into a corresponding halide. This method comprises reacting the alcohol with an optionally substituted aromatic carboxylic acid halide in presence of an N-substituted formamide to replace a hydroxyl group of the alcohol by a halogen atom. The present invention also relates to a method of converting an alcohol into a corresponding substitution product. The second method comprises: (a) performing the method of the invention of converting an alcohol into the corresponding halide; and (b) reacting the corresponding halide with a nucleophile to convert the halide into the nucleophilic substitution product.

  本发明涉及一种将醇转化为相应卤化物的方法。该方法包括在N-取代甲酰胺的存在下，将醇与可选择取代的芳香羧酸卤化物反应，以通过卤原子取代醇的羟基。本发明还涉及一种将醇转化为相应取代产物的方法。第二种方法包括：(a)执行将醇转化为相应卤化物的本发明方法；以及(b)将相应卤化物与亲核试剂反应，将卤化物转化为亲核取代产物。
• Novel compositions for the delivery of negatively charged molecules
  申请人：Ribozyme Pharmaceuticals, Inc.

  公开号：US20030073640A1

  公开（公告）日：2003-04-17

  This invention features permeability enhancer molecules, and methods, to increase membrane permeability of various molecules, such as nucleic acids, polynucleotides, oligonucleotides, enzymatic nucleic acid molecules, antisense nucleic acid molecules, 2-5A antisense chimeras, triplex forming oligonucleotides, decoy RNAs, dsRNAs, siRNAs, aptamers, or antisense nucleic acids containing nucleic acid cleaving chemical groups, peptides, polypeptides, proteins, carbohydrates, steroids, metals and small molecules, thereby facilitating cellular uptake of such molecules.

  本发明涉及一种透过性增强剂分子，及其方法，用于增加诸如核酸、多核酸、寡核酸、酶核酸分子、反义核酸分子、2-5A反义嵌合体、三链形成寡核酸、诱饵RNA、双链RNA、小干扰RNA、适配体或含有核酸切割化学基团的核酸、肽、多肽、蛋白质、碳水化合物、类固醇、金属和小分子等不同分子的膜透过性，从而促进细胞对这些分子的摄取。